Skip to main content Skip to main navigation menu Skip to site footer

Apoptosis evasion and local recurrence after mastectomy and chemotherapy in lobular type breast cancer. A cross-sectional study in a single-center

Abstract

Link of Video Abstract: https://www.youtube.com/watch?v=Ws-SVwmrhs0

Background
: Lobular type breast cancer (ILC) was the second most common type after ductal breast cancer. Chemotherapy may be used to lower the risk of recurrence in addition to surgery, which is the main treatment for early-stage breast cancer. Apoptosis is one of the body's techniques for killing cancer cells; thus, cancer cells must be able to evade it to survive. Due to the rarity of the disease, it is uncommon for researchers to investigate ILC, especially at an early stage. This study aimed to determine the mechanism of apoptosis evasion in ILC after mastectomy and chemotherapy who got local recurrence within two years after surgery by analyzing the expression of vimentin, IL 10, and CD 95.

Methods: This research was a cross-sectional study of medical records in a single center. The sampling method was total sampling, i.e., all patients underwent a mastectomy and received chemotherapy from January 2014 to December 2019 (5 years). Immunohistochemistry analysis was used to check the vimentin, α-IL10, and CD 95 levels in paraffin blocks from surgical tissues. A chi-square test and a path analysis with a linear regression test were the statistical tests used in this study.

Results: Seven samples contained local recurrence, while only six did not. According to statistical tests, the expression of vimentin, IL10, and CD95 between the recurrence and non-recurrence groups was significantly different. The chi-square test showed CD95 is a protective factor for local recurrence (odds ratio [OR] = 0.03, 95% confidence interval [CI] = 0.002-0.68 p =0.001). The multivariate analysis showed that vimentin expression has a significantly strong correlation with IL10 expression (p=0.000); the IL10 expression has a significant negative correlation to CD95 expression (p=0.03); and the CD95 expression was strongly correlated with the local recurrence (p=0.001).

Conclusion: Apoptosis evasion had an important role in the local recurrence of ILC after mastectomy and chemotherapy.

References

  1. Ekassiana PMK, Supadmanaba IGP, Wihandani DM, Adiputra PAT. The association between Caveolin-1 expressions with clinicopathological characteristic of breast cancer. Bali Medical Journal. 2019;8(3):S774–9.
  2. Wintoko R, Susilo H. The relationship of hormonal receptor, HER-2, and KI-67 changes after administration of anthracycline-based neoadjuvant chemotherapy with the results of histopathological grading in stage III breast cancer patients at Saiful Anwar Malang Regional Public H. Bali Medical Journal. 2019;8(3):S788–94.
  3. Sadeghian Y, Samizadeh E, Mohammadi-vajari MAA, Lashkari MH, Sadeghian E, Hosseini SN, et al. Association between expression of ALDH1 and TGFb2 genes, histological and clinical findings in breast cancer. Bali Medical Journal. 2019;8(3):813–7.
  4. Sousa B, Pereira J, Marques R, Grilo LF, Pereira SP, Sardão VA, et al. P-cadherin induces anoikis-resistance of matrix-detached breast cancer cells by promoting pentose phosphate pathway and decreasing oxidative stress. Biochim Biophys Acta Mol Basis Dis. 2020;1866(12):165964.
  5. Wilson N, Ironside A, Diana A, Oikonomidou O. Lobular Breast Cancer: A Review. Vol. 10, Frontiers in Oncology. Frontiers Media S.A.; 2021.
  6. Al-Hilli Z, Grobmyer SR. Management Strategies for Locally Recurrent Breast Cancer: Redo-Lumpectomy, Redo-Sentinel Node Biopsy, Redo-Radiation. Ann Surg Oncol. 2019;26(10):3018–24. Available from: https://doi.org/10.1245/s10434-019-07545-y
  7. Hassan MSU, Ansari J, Spooner D, Hussain SA. Chemotherapy for breast cancer (review). Vol. 24, Oncology Reports. Spandidos Publications; 2010. p. 1121–31.
  8. Kallergi G, Papadaki MA, Politaki E, Mavroudis D, Georgoulias V, Agelaki S. Epithelial to mesenchymal transition markers expressed in circulating tumour cells of early and metastatic breast cancer patients. Breast Cancer Research. 2011;13(3).
  9. Panigoro SonarS, Karsono R, Sari L. E-cadherin and Vimentin as Predictors of Resistance to Preoperative Systemic Therapy in Patients with Advanced Breast Cancer. eJournal Kedokteran Indonesia. 2017;4(3):27–30.
  10. Theodoropoulos GE, Saridakis V, Karantanos T, Michalopoulos N V., Zagouri F, Kontogianni P, et al. Toll-like receptors gene polymorphisms may confer increased susceptibility to breast cancer development. Breast. 2012;21(4):534–8.
  11. Igney FH, Krammer PH. Immune escape of tumors: apoptosis resistance and tumor counterattack. J Leukoc Biol. 2002;71(6):907–20.
  12. Rui Z. ReproducibilityoftheNotingham modificationoftheScarf- Bloom—Richardsonhistologicalgradingsystem andthe com plem entary value ofK i一67 to this system. Chin Med J (Engl). 2011;123(15):35–44.
  13. Kanda Y. Investigation of the freely available easy-to-use software “EZR” for medical statistics. Bone Marrow Transplant. 2013;48(3):452–8.
  14. Ren´ R, Mulder RL, Hudson MM, Bhatia S, Landier W, Levitt ; Gill, et al. Updated Breast Cancer Surveillance Recommendations for Female Survivors of Childhood, Adolescent, and Young Adult Cancer From the International Guideline Harmonization Group. J Clin Oncol. 2020;38:4194–207. Available from: https://doi.
  15. Acheampong T, Kehm RD, Terry MB, Argov EL, Tehranifar P. Incidence Trends of Breast Cancer Molecular Subtypes by Age and Race/Ethnicity in the US From 2010 to 2016. JAMA Netw Open. 2020;3(8):e2013226.
  16. Jones T, Neboori H, Wu H, Yang Q, Haffty BG, Evans S, et al. Are breast cancer subtypes prognostic for nodal involvement and associated with clinicopathologic features at presentation in early-stage breast cancer? Vol. 20, Annals of Surgical Oncology. 2013. p. 2866–72.
  17. Mego M, Gao H, Lee BN, Cohen EN, Tin S, Giordano A, et al. Prognostic value of EMT-circulating tumor cells in metastatic breast can-cer patients undergoing high-dose chemotherapy with autologous hematopoietic stem cell transplantation. J Cancer. 2012;3(1):369–80.
  18. Tam WL, Lu H, Buikhuisen J, Soh BS, Lim E, Reinhardt F, et al. Protein Kinase C α Is a Central Signaling Node and Therapeutic Target for Breast Cancer Stem Cells. Cancer Cell. 2013;24(3):347–64.
  19. Creighton CJ, Li X, Landis M, Dixon JM, Neumeister VM, Sjolund A, et al. Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proceedings of the National Academy of Sciences. 2009;106(33):13820–5.
  20. Carneiro BA, El-Deiry WS. Targeting apoptosis in cancer therapy. Vol. 17, Nature Reviews Clinical Oncology. Nature Research; 2020. p. 395–417.
  21. Lakhtakia R, Aljarrah A, Furrukh M, Ganguly SS. Epithelial Mesenchymal Transition (EMT) in Metastatic Breast Cancer in Omani Women. Cancer Microenvironment. 2017;10(1–3):25–37.
  22. Whipple RA, Balzer EM, Cho EH, Matrone MA, Yoon JR, Martin SS. Vimentin filaments support extension of tubulin-based microtentacles in detached breast tumor cells. Cancer Res. 2008;68(14):5678–88.
  23. Korobeinikova E, Myrzaliyeva D, Ugenskiene R, Raulinaityte D, Gedminaite J, Smigelskas K, et al. The prognostic value of IL10 and TNF alpha functional polymorphisms in premenopausal early-stage breast cancer patients. BMC Genet. 2015;16(1).
  24. Giacomelli L, Gianni W, Belfiore C, Gandini O, Repetto L, Filippini A, et al. Persistence of Epidermal Growth Factor Receptor and Interleukin 10 in Blood of Colorectal Cancer Patients after Surgery Identifies Patients with High Risk to Relapse 1. 2003.
  25. Zhang L, Liu W, Wang X, Wang X, Sun H. Prognostic value of serum IL-8 and IL-10 in patients with ovarian cancer undergoing chemotherapy. Oncol Lett. 2019;17(2):2365–9.
  26. Zhang Y, Zheng Y, Shou L, Shi Y, Shen H, Zhu M, et al. Increased Serum Level of Interleukin-10 Predicts Poor Survival and Early Recurrence in Patients With Peripheral T-Cell Lymphomas. Front Oncol. 2020;10.
  27. Song J, Lin Z, Liu Q, Huang S, Han L, Fang Y, et al. MiR‐192‐5p/RB1/NF‐κBp65 signaling axis promotes IL‐10 secretion during gastric cancer EMT to induce Treg cell differentiation in the tumour microenvironment. Clin Transl Med. 2022;12(8).
  28. Yamana K, Bilim V, Hara N, Kasahara T, Itoi T, Maruyama R, et al. Prognostic impact of FAS/CD95/APO-1 in urothelial cancers: Decreased expression of Fas is associated with disease progression. Br J Cancer. 2005;93(5):544–51.
  29. Strater J, Hinz U, Bhanot U, Mechtersheimer G, Lehnert T, Möller P, et al. Impaired CD95 expression predisposes for recurrence in curatively resected colon carcinoma: clinical evidence for immunoselection and CD95L mediated control of minimal residual disease. Gut. 2005;54(5):661–5.
  30. HOOGWATER FJH, SNOEREN N, NIJKAMP M, KRANENBURG O, RINKES I. Circulating CD95-ligand as a Potential Prognostic Marker for Recurrence in Patients with Synchronous Colorectal Liver Metastases. ANTICANCER RESEARH. 2011;31(1):4507–12. Available from: https://ar.iiarjournals.org/content/anticanres/31/12/4507.full.pdf

How to Cite

Andrianto, A., Sudiana, I. K., & Suprabawati, D. G. A. (2023). Apoptosis evasion and local recurrence after mastectomy and chemotherapy in lobular type breast cancer. A cross-sectional study in a single-center. Bali Medical Journal, 12(3), 2690–2695. https://doi.org/10.15562/bmj.v12i3.4766

HTML
7

Total
6

Share

Search Panel

Andreas Andrianto
Google Scholar
Pubmed
BMJ Journal


I Ketut Sudiana
Google Scholar
Pubmed
BMJ Journal


Desak Gede Agung Suprabawati
Google Scholar
Pubmed
BMJ Journal